Drug Trial Radar · NCT01918033
A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)
Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
608
Actual
Start
Aug 20, 2013
Primary completion
Jan 26, 2014
Study completion Jan 26, 2014
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine is superior to placebo after 2 weeks of treatment with regard to change from baseline in Total Nasal Symptom Score among Japanese participants with perennial allergic rhinitis.
Conditions
- Perennial Allergic Rhinitis
Interventions
Desloratadine 5 mgDrug
Desloratadine 5 mg tablets
PlaceboDrug
Matching placebo to desloratadine 5 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2Time frame: Baseline and Week 2
- Number of Participants Experiencing an Adverse Event (AE)Time frame: Up to Week 4
- Number of Participants Discontinuing Study Drug Due to an AETime frame: Up to Week 2
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.